----item----
version: 1
id: {744B5846-B5E6-47DB-86F0-FE29EC2E5A23}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/16/AZ to test checkpoint inhibitors with Immunocores TCR candidate
parent: {D1C4EE2F-AEA4-438A-AF54-BB06F27BAC15}
name: AZ to test checkpoint inhibitors with Immunocores TCR candidate
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: ccc8c3bd-6e9c-4949-9720-52daf920f745

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 64

AZ to test checkpoint inhibitors with Immunocore's TCR candidate
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 63

AZ to test checkpoint inhibitors with Immunocores TCR candidate
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1894

<p>AstraZeneca, via its MedImmune unit, has entered a second collaboration with promising UK biotech Immunocore in the area of immune-oncology. Under the new agreement, Immunocore will conduct a Phase Ib/II trial combining AstraZeneca's investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore's lead T-cell receptor based therapeutic candidate, for the potential treatment of metastatic melanoma. MedImmune will have first right of negotiation for the future commercial development of these combinations for tumours expressing gp100. The companies have a <a href="http://C:\Users\virjis\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.IE5\4BDSBXB5\. http:\www.scripintelligence.com\business\AZ-third-big-pharma-to-strike-deal-for-Immunocores-T-Cell-technology-349156" target="_new">pre-existing agreement</a>, announced in January 2014, to develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology</p><p><b>Related stories</b></p><p><a href="http://www.scripintelligence.com/home/Act-now-for-a-sustainable-future-JP-Morgans-European-healthcare-boss-tells-UK-firms-356536" target="_new">'Act now for a sustainable future', JP Morgan's European healthcare boss tells UK firms</a></p><p><a href="http://www.scripintelligence.com/business/Immunocore-attracts-Lilly-in-co-co-deal-352895" target="_new">Immunocore attracts Lilly in co-co deal</a></p><p><a href="http://www.scripintelligence.com/home/AACR-PREVIEW-Immuno-oncology-commands-respect-351042" target="_new">AACR PREVIEW: Immuno-oncology commands respect</a></p><p><a href="http://www.scripintelligence.com/business/AZ-third-big-pharma-to-strike-deal-for-Immunocores-T-Cell-technology-349156" target="_new">AZ third big pharma to strike deal for Immunocore's T-Cell technology</a></p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 813

<p>AstraZeneca, via its MedImmune unit, has entered a second collaboration with promising UK biotech Immunocore in the area of immune-oncology. Under the new agreement, Immunocore will conduct a Phase Ib/II trial combining AstraZeneca's investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore's lead T-cell receptor based therapeutic candidate, for the potential treatment of metastatic melanoma. MedImmune will have first right of negotiation for the future commercial development of these combinations for tumours expressing gp100. The companies have a <a>pre-existing agreement</a>, announced in January 2014, to develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 63

AZ to test checkpoint inhibitors with Immunocores TCR candidate
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150416T080000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150416T080000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150416T080000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028444
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 64

AZ to test checkpoint inhibitors with Immunocore's TCR candidate
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{20E0B55E-5592-4DBF-A9D4-58B471A17E67}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357813
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042330Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

ccc8c3bd-6e9c-4949-9720-52daf920f745
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042330Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
